Reducing the Incidence of Acute Kidney Injury from Vancomycin & Pip/Tazo
FEB 08, 2017 | CONTAGION EDITORIAL STAFF
Megan Luther, PharmD, Advanced Health Services research fellow, Providence Veterans Affairs Medical Center, University of Rhode Island, College of Pharmacy, discusses potential strategies to reduce incidence of acute kidney injuries due to vancomycin and pip/tazo combination therapy.
Interview Transcript (slightly modified for readability)
“I think from a basic [scientific] standpoint we need to figure out what exactly the mechanism is, why [the combination of vancomycin and piperacillin/tazobactam] causes more acute kidney injury than either of the two components alone. We’re back to the bench, basically, to figure out what exactly that mechanism is.
From a clinical standpoint, I think [we need to make] sure that we have antimicrobial stewardship teams looking at and narrowing therapy before day 4 to 7 and [make] sure that we can decrease the acute kidney injury incidence and get stewardship teams on board.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512